Alkermes stock jumps 3% premarket after FDA approves injectable schizophrenia treatment [MarketWatch]
Alkermes plc - Ordinary Shares (ALKS)
Last alkermes plc - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-irhome
Company Research
Source: MarketWatch
Alkermes stock jumps 3% premarket after FDA approves injectable schizophrenia treatment Alkermes Plc shares ALKS, +0.88% rose about 3% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has approved its long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults. "For the first time, ARISTADA INITIO, in combination with a single 30 mg dose of oral aripiprazole, provides physicians with an alternative regimen to initiate patients onto any dose of ARISTADA on day one," the company said in a statement. The treatment is expected to support schizophrenia patients who have difficulties with medication complicance and continuity of care, notably for those moving from inpatient to outpatient care. "The approval of ARISTADA INITIO makes ARISTADA the first and only long-acting atypical antipsychotic that can be initiated on day one, representing an important addition to the treatment paradigm for the complex illness of schiz
Show less
Read more
Impact Snapshot
Event Time:
ALKS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALKS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALKS alerts
High impacting Alkermes plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ALKS
News
- Alkermes plc (NASDAQ: ALKS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.MarketBeat
- Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]Yahoo! Finance
- Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo NordiskPR Newswire
- Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo NordiskPR Newswire
ALKS
Earnings
- 5/1/24 - Miss
ALKS
Sec Filings
- 5/1/24 - Form 10-Q
- 5/1/24 - Form 8-K
- 4/15/24 - Form ARS
- ALKS's page on the SEC website